Given the above examples, it is now more clear that ROR1 expression triggers disease progression and drug resistance via CSC development, suggesting that ROR1 could also be used as a CSC marker, at least for some tumors such as breast and ovarian cancers. The gene discussed is ROR1; the disease is ovarian carcinoma.